Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice

Blood

Volumn 93, Issue 6, 1999, Pages 2043-2056

  MacKenzie, K L ^b   Dolnikov, A ^b   Millington, M ^b   Shounan, Y ^b   Symonds, G ^a  

^a JOHNSON AND JOHNSON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; COLONY FORMING UNIT S; DISEASE MODEL; ERYTHROPOIESIS; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; LEUKEMOGENESIS; LYMPHOCYTOPENIA; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE N RAS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THYMUS ATROPHY;

EID: 0033559734     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.6.2043.406k17_2043_2056     Document Type: Article

References (62)

1. Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, Kamata T, Feramisco J, Stavnezer E, Fogh J, Wigler MH: Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci USA 80:2112, 1983
2. Lowry DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem 62:851, 1993
3. Mandanas RA, Leibowitz DS, Gharenhbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 82:1838, 1992
4. Moodie SA, Willumsen BM, Weber MJ, Wolfman A: Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260:1658, 1993
5. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527, 1994
6. Spaargaren M, Bischoff JR: Identification of the guanine nucleotide dissociation stimulator for Raf as putative effector molecule of R-ras, H-ras, K-ras, and RAP. Proc Natl Acad Sci USA 91:12609, 1994
7. Ras with Jun N-terminal kinase and Jun proteins. Proc Natl Acad Sci USA 92:10585, 1995
8. Bos JL: ras Oncogenes in human cancer: A review. Cancer Res 49:4682, 1989
9. Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, van der Eb AJ, van Boom JH, Janssen JWG, Steenvoorden ACM: Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315:726, 1985
10. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, Mizoguchi H, Nishida J, Takaku F: A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327:430, 1987
11. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA: RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214, 1990
12. Gishizky ML, Cortez D, Pendergast AM: Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 92:10889, 1995
13. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The BCR-ABL leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92:11746, 1995
14. Basu TN, Gutman DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713, 1992
15. Bollag G, Clapp DW, Shih S, Alder F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McMormick F, Jacks T, Shannon K: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144, 1997
16. Golub TR, Barker GF, Lovett M, Gilliand DG: Fusion of the PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307, 1994
17. Bashey A, Gill R, Levi S, Farr CJ, Clutterbuck R, Millar JL, Pragnell IB, Marshall CJ: Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): Implications for the role of N-ras mutation in AML pathogenesis. Blood 79:981, 1992
18. Maher J, Colonna F, Baker D, Luzzato L, Roberts I: Retroviral-mediated transfer of mutant H-ras gene into normal human bone marrow alters myeloid cell proliferation and differentiation. Exp Hematol 22:8, 1994
19. Andrejauskas E, Moroni C: Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. EMBO J 8:2575, 1989
20. Dunbar CE, Crosier PS, Nienhuis AW: Introduction of an activated ras oncogene into murine BM lymphoid progenitors via retroviral gene transfer results in thymic lymphomas. Oncogene Res 6:39, 1991
21. Hibi S, Löhler J, Friel J, Stocking C, Ostertag W: Induction of monocytic differentiation and tumorigenicily by v-Ha-ras in differentiation-arrested hematopoietic cells. Blood 81:1841, 1993
22. Hawley RG, Fong AZC, Ngang B-Y, Hawley TS: Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene 11:1113, 1995
23. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IAG: Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 11:1639, 1995
24. Harris AW, Langdon WY, Alexander WS, Hariharan IK, Rosenberg H, Vaux D, Webb E, Bernard O, Crawford M, Abud H, Adams JM, Cory S: Transgenic mouse models for hematopoietic tumorigenesis. Curr Top Microbiol Immunol 141:82, 1988
25. Mangues R, Symmans WF, Lu S, Schwartz S, Pellicer A: Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene 13:1053, 1996
26. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R: Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85:9268, 1988
27. Bender MA, Palmer TD, Gelinas RE, Miller AD: Evidence that the packaging signal of Moloney murine leukaemia virus extends into the gag region. J Virol 61:1639, 1987
28. Chisholm O, Symonds G: An in vitro fibroblast model system to study myc driven tumour progression. Int J Cancer 51:149, 1992
29. Danos O, Mulligan RC: Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460, 1988
30. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1990
31. Bonham L, MacKenzie K, Wood S, Rowe PB, Symonds G: Both myeloproliferative disease and leukemia are induced by transplantation of bone marrow cells expressing v-myc. Oncogene 7:2219, 1992
32. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992
33. MacKenzie KL, Bonham L, Symonds G: An internal deletion enhances the transcriptional activity of a recombinant retrovirus in hematopoietic cells in vivo. J Virol 68:6924, 1994
34. Apperley JF, Luskey BD, Williams DA: Retroviral gene transfer of human adenosine deaminase in murine haematopoietic cells: Effect of selectable marker sequences on long-term expression. Blood 78:310, 1991
35. Ohashi T, Boggs S, Robbins P, Bahnson A, Patrene K, Wei F-S, Wei J-F, Li J, Lucht L, Fei Y, Clark S, Kimak M, He H, Mowery-Rushton P, Barranger JA: Efficient transfer and sustained high expression of the human cerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 89:1132, 1992
36. Shounan Y, Dolnikov A, MacKenzie KL, Miller M, Chan Y-Y, Symonds G: Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potenital and inhibits apoptosis. Leukemia 10:1619, 1996
37. Dolnikov A, Shounan Y, Millington M, MacKenzie KL, Symonds G: v-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation. Leukemia 12:542, 1998
38. d mice as a single factor. Blood 79:913, 1992
39. Till JE, McCulloch EA: A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213, 1961
40. Darley RL, Hoy TG, Baines P, Padua RA, Burnett AK: Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med 185:1337, 1997
41. Duménil D, Neel H, Lacout C, Dautry F: Infection with a Kirsten-retrovirus can induce a multiplicity of tumorigenic phenotypes in the interleukin-3-dependent FDC-P1 cells. Exp Hematol 22:178, 1994
42. Land H, Parada LF, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 222:771, 1983
43. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two co-operating oncogenes. Nature 304:596, 1983
44. Hirakawa T, Ruley HE: Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene. Proc Natl Acad Sci USA 85:1519, 1988
45. Pumiglia KM, Decker SJ: Cell cycle arrest mediated by the MEK/mitogen activated protein kinase pathway. Proc Natl Acad Sci USA 94:488, 1997
46. Champlin RE, Golde DW: Chronic myelogenous leukemia: Recent advances. Blood 65:1039, 1985
47. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. Br J Haematol 33:451, 1976
48. van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CHW, Kerkhofs H, Willemze R, Fibbe WE, Landegent JE: Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 79:1266, 1992
49. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, Yamane Y, Inazawa J, Abe T, Kashima K: N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8:1331, 1994
50. Nand S, Godin JE: Hypoplastic myelodysplastic syndrome. Cancer 62:958, 1988
51. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoieitc cells in 50 patients with myelodysplastic syndrome. Blood 86:268, 1995
52. bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
53. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069, 1990
54. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 87:6649, 1990
55. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: Nfl deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat Genet 12:137, 1996
56. Elefanty AG, Cory S: Hematologic disease induced in BALB/c mice by a bcr/abl retrovirus is influenced by the infection conditions. Mol Cell Biol 12:1755, 1992
57. Karla R, Paderanga DC, Olson K, Shannon KM: Genetic analysis is consistent with the hypothesis that NF1 limits myeloid growth through p21 ras. Blood 84:3435, 1994
58. Adams JM, Cory S: Transgenic models for haemopoietic malignancies. Biochim Biophys Acta 1072:9, 1991
59. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myr genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465, 1987
60. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T: Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829, 1994
61. Ferrari G, Greene LA: Proliferative inhibition by dominant-negative Ras rescues naive and neuronally differentiated PC12 cells from apoptotic death. EMBO J 13:5922, 1994
62. Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, Shih TS, Jacks T, Pawson T: Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. Nature 377:695, 1995